

Curriculum Vitae

Personal information **Dario Trapani**

Work experience

1. Employer: World Health Organization
 - Start date: 022018
 - End date: 092020
 - Position: Consultant for cancer, Management of Cancer
 - Activities: Cancer control planning, essential medicines, essential diagnostics, health planning, clinical guidelines.
 - Country: Switzerland
2. Employer: European Institute of Oncology (IEO),
 - Start date: 032020
 - End date:
 - Position: Medical Oncologist
 - Activities: medical oncologist, clinical researcher
 - Country: Italy
3. Employer: Dana Farber Cancer Institute
 - Start date: 072021
 - End date: 012023
 - Position: research fellow
 - Activities: research and clinical practice, in the department of breast oncology
 - Country: United States

Education and training

1. Subject: European Institute of oncology (IEO)
 - Start date: 062015
 - End date: 012019
 - Qualification: Medical oncology training
 - Organisation: Medical oncology training, medical oncology residency program at University of Milan and Early drug development for innovative therapies program, phase 1 clinical trials division.
 - Country: Italy
2. Subject: University of Milan, La Statale
 - Start date: 112014
 - End date: 062015
 - Qualification: internal and emergency medicine _ clinical rotation
 - Organisation: University Hospital "Sacco", internal and emergency medicine.
 - Country: Italy
3. Subject: University of Salerno, University Hospital
 - Start date: 012011
 - End date: 052014
 - Qualification: medical internship
 - Organisation: Dept of Medical Oncology
 - Country: Italy

Additional information

Publications

1. Duggan C, Trapani D, Ilbawi AM, Fidarova E, Laversanne M, Curigliano G, Bray F, Anderson BO. National health system characteristics, breast cancer stage at diagnosis, and breast cancer mortality: a population based analysis. *Lancet Oncol.* 2021 Nov;22(11):1632_1642. doi: 10.1016/S1470_2045(21)00462_9. Epub 2021 Oct 13. PMID: 34653370.
2. van der Hage J, Sandrucci S, Audisio R, Wyld L, Søreide K; ESSO core curriculum contributors, Amaral T, Audisio R, Bahadoer V, Beets G, Benstead K, Berge Nilsen E, Bol K, Brandl A, Braun J, Cufer T, Dopazo C, Edhemovic I, Eriksen JG, Fiore M, van Ginhoven T, Gonzalez Moreno S, van der Hage J, Hutteman M, Masannat Y, Onesti EC, Rau B, De Reijke T, Rubio I, Ruurda J, Sandrucci S, Soreide K, Stattner S, Trapani D, D'Ugo D, Vriens M, Wyld L, Zahl Eriksson AG. The ESSO core curriculum committee update on surgical oncology. *Eur J Surg Oncol.* 2021 Oct 13:S0748_7983(21)00753_8. doi: 10.1016/j.ejso.2021.10.003. Epub ahead of print. PMID: 34657781.
3. Fundytus A, Sengar M, Lombe D, Hopman W, Jalink M, Gyawali B, Trapani D, Roitberg F, De Vries EGE, Moja L, Ilbawi A, Sullivan R, Booth CM. Access to cancer medicines deemed essential by oncologists in 82 countries: an international, cross sectional survey. *Lancet Oncol.* 2021 Oct;22(10):1367_1377. doi: 10.1016/S1470_2045(21)00463_0. Epub 2021 Sep 21. PMID: 34560006; PMCID: PMC8476341.
4. Trapani D, Curigliano G. COVID_19 vaccines in patients with cancer. *Lancet Oncol.* 2021 Jun;22(6):738_739. doi: 10.1016/S1470_2045(21)00250_3. PMID: 34087120; PMCID: PMC8169039.
5. Trapani D, Yves Douillard J, Winer EP, Burstein H, Anne Carey L, Cortes J, Lopes G, Gralow JR, Gradishar WJ, Magrini N, Curigliano G & Ilbawi AM. The global landscape of treatment standards for breast cancer. *J Natl Cancer Inst.* 2021 Jan 27:djab011. doi: 10.1093/jnci/djab011. Epub ahead of print. PMID: 33502535.
6. Trapani D, C.G.Lengyel, B.S.Habeeb, S.C.Altuna, A.Petrillof, El Bairi, S.Hussain, S.A.Mazheri, E.M.Elfehham, G.Curigliano, S.Z.Khan. The global landscape of availability, accessibility and affordability of essential diagnostics and therapeutics for the management of HER2 positive breast cancer: The ONCOLLEGE_001 survey. June 2021. <https://doi.org/10.1016/j.jcpo.2021.100285>
7. Trapani D, Curigliano G. The global landscape of drug development of trastuzumab biosimilars. *J Cancer Policy* Volume 28, June 2021, 100273.
8. Nicolò E, Trapani D, Berton Giachetti PPM, Zagami P, Curigliano G. Fed or fasted state for oral therapies in breast cancer treatment? A comprehensive review of clinical practice recommendations. *Cancer Treat Rev.* 2021 Aug 18;100:102281. doi: 10.1016/j.ctrv.2021.102281. Epub ahead of print. PMID: 34500366.
9. Gyawali B, de Vries EGE, Dafni U, Amaral T, Barriuso J, Bogaerts J, Calles A, Curigliano G,

Gomez_Roca C, Kiesewetter B, Oosting S, Passaro A, Pentheroudakis G, Piccart M, Roitberg F, Tabernero J, Tarazona N, Trapani D, Wester R, Zarkavelis G, Zielinski C, Zygora P, Cherny NI. Biases in study design, implementation, and data analysis that distort the appraisal of clinical benefit and ESMO_Magnitude of Clinical Benefit Scale (ESMO_MCBS) scoring. *ESMO Open*. 2021 Apr 19;6(3):100117. doi: 10.1016/j.esmoop.2021.100117. Epub ahead of print. PMID: 33887690; PMCID: PMC8086024. 10. Trapani D, Giugliano F, Uliano J, Zia VAA, Marra A, Viale G, Ferraro E, Esposito A, Criscitiello C, D'Amico P, Curigliano G. Benefit of adjuvant chemotherapy in patients with special histology subtypes of triple_negative breast cancer: a systematic review. *Breast Cancer Res Treat*. 2021 Jun;187(2):323_337. doi: 10.1007/s10549_021_06259_8. Epub 2021 May 27. PMID: 34043122. 11. Trapani D, Gandini S, Corti C, Crimini E, Bellerba F, Minchella I, Criscitiello C, Tarantino P, Curigliano G. Benefit of adjuvant chemotherapy in patients with lobular breast cancer: A systematic review of the literature and metanalysis. *Cancer Treat Rev*. 2021 Jun;97:102205. doi: 10.1016/j.ctrv.2021.102205. Epub 2021 Apr 9. PMID: 33878560. 12. Tarantino P, Trapani D, Curigliano G. Mastering the Use of Novel Anti_HER2 Treatment Options. *JCO Oncol Pract*. 2021 Jun 2:OP2100216. doi: 10.1200/OP.21.00216. Epub ahead of print. PMID: 34077256. 13. Yekedüz E, Trapani D, Xu W, de Vries EG, Labaki C, Gyawali B, Gulati S, Nabhan C, Utkan G, Curigliano G, Choueiri TK, Ürün Y. Assessing Population Diversity in Phase III Trials of Cancer Drugs Supporting FDA Approval in Solid Tumors. *Int J Cancer*. 2021 Jun 14. doi: 10.1002/ijc.33708. Epub ahead of print. PMID: 34124786. 14. Filetti M, Trapani D, Cortellini A, Cofini V, Necozione S, James Pinato D, Porzio G, Marchetti P, Giusti R. Knowledge and attitudes of Italian medical oncologists and palliative care physicians toward medical use of cannabis in cancer care: a national survey. *Support Care Cancer*. 2021 Jun 26. doi: 10.1007/s00520_021_06383_7. Epub ahead of print. PMID: 34176017. 15. Vernieri C, Nichetti F, Lalli L, Moscetti L, Giorgi CA, Griguolo G, Marra A, Randon G, Rea CG, Ligorio F, Scagnoli S, De Angelis C, Molinelli C, Fabbri A, Ferraro E, Trapani D, Milani A, Agostinetti E, Bernocchi O, Catania G, Vantaggiato A, Palleschi M, Moretti A, Basile D, Cinausero M, Ajazi A, Castagnoli L, Lo Vullo S, Gerrata L, Puglisi F, La Verde N, Arpino G, Rocca A, Ciccarese M, Pedersini R, Fabi A, Generali D, Losurdo A, Montemurro F, Curigliano G, Del Mastro L, Michelotti A, Cortesi E, Guarneri V, Pruner G, Mariani L, de Braud F. Impact of Baseline and On_Treatment Glycemia on Everolimus_Exemestane Efficacy in Patients with Hormone Receptor_Positive Advanced Breast Cancer (EVERMET). *Clin Cancer Res*. 2021 Jun 15;27(12):3443_3455. doi: 10.1158/1078_0432.CCR_20_4928. Epub 2021 Mar 30. PMID: 33785482. 16. Giugliano F, Crimini E, Tarantino P, Zagami P, Uliano J, Corti C, Trapani D, Curigliano G. First line treatment of BRAF mutated advanced melanoma: Does one size fit all? Cancer treatment reviews, Sept 2021. 17. Safi M, Al_Nusaif M, Trapani D, Mashrah MA, Kanesvaran R, Alzandani A, Al_Azab M, Mazher SA, Al_Danakh A, Liu J. Brain and heart specific death in cancer patients: Population_based study. *Cancer Med*. 2021 Sep;10(17):5739_5747. doi: 10.1002/cam4.4069. Epub 2021 Aug 10. PMID: 34374226; PMCID: PMC8419745. 18. Safi M, Trapani D, Alradhi M, Shan X, Jiwei L. Letter to the editor: No Overall Survival Difference in the Immunotherapy Era for Rare Subtypes of Melanoma. *Pathol. Oncol. Res*. 2021 19. Elit L, Haruyama R, Gatti A, Howard SC, Lam CG, Fidarova E, Angioli R, Cao X, Trapani D, Ilbawi A. Examining policy cohesion for cervical cancer worldwide: analysis of WHO country reports. *ESMO Open*. 2020 Nov;5(6):e000878. doi: 10.1136/esmoopen_2020_000878. PMID: 33310778; PMCID: PMC7783605. 20. Marra A, Trapani D, Viale G, Criscitiello C, Curigliano G. Practical classification of triple_negative breast cancer: intratumoral heterogeneity, mechanisms of drug resistance, and novel therapies. *NPJ Breast Cancer*. 2020 Oct 16;6:54. doi: 10.1038/s41523_020_00197_2. PMID: 33088912; PMCID: PMC7568552. 21. Tarantino P, Mazzaella L, Marra A, Trapani D, Curigliano G. The evolving paradigm of biomarker actionability: Histology_agnosticism as a spectrum, rather than a binary quality. *Cancer Treat Rev*. 2021 Feb 20;94:102169. doi: 10.1016/j.ctrv.2021.102169. Epub ahead of print. PMID: 33652262. 22. Tarantino P, Gandini S, Trapani D, Criscitiello C, Curigliano G. Immunotherapy addition to neoadjuvant chemotherapy for early triple negative breast cancer: a systematic review and meta_analysis of randomized clinical trials. *Crit Rev Oncol Hematol*. 2021 Jan 19:103223. doi: 10.1016/j.critrevonc.2021.103223. Epub ahead of print. PMID: 33482345. 23. Ghidini M, Fusco N, Salati M, Khakoo S, Tomasello G, Petrelli F, Trapani D, Petrillo A. The Emergence of Immune_checkpoint Inhibitors in Colorectal Cancer Therapy. *Curr Drug Targets*. 2021 Feb 4. doi: 10.2174/1389450122666210204204415. Epub ahead of print. PMID: 33563194. 24. Indini A, Nigro O, Lengyel CG, Ghidini M, Petrillo A, Lopez S, Raspagliesi F, Trapani D, Khakoo S, Bogani G. Immune_Checkpoint Inhibitors in Platinum_Resistant Ovarian Cancer. *Cancers (Basel)*. 2021 Apr 1;13(7):1663. doi: 10.3390/cancers13071663. PMID: 33916221; PMCID: PMC8037571. 25. Ghidini M, Petrillo A, Botticelli A, Trapani D, Parisi A, La Salvia A, Sajjadi E, Piciotti R, Fusco N, Khakoo S. How to Best Exploit Immunotherapeutics in Advanced Gastric Cancer: Between Biomarkers and Novel Cell_Based Approaches. *J Clin Med*. 2021 Apr 1;10(7):1412. doi: 10.3390/jcm10071412. PMID: 33915839; PMCID: PMC8037391. 26. Lengyel CG, Hussain S, Trapani D, El Bairi K, Altuna SC, Seebor A, Odhiambo A, Habeeb BS, Seid F. The Emerging Role of Liquid Biopsy in Gastric Cancer. *J Clin Med*. 2021 May 13;10(10):2108. doi: 10.3390/jcm10102108. PMID: 34068319; PMCID: PMC8153353. 27. Petrillo A, Salati M, Trapani D, Ghidini M. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. *Curr Drug Targets*. 2020 Nov 3. doi: 10.2174/1389450121999201103194248. Epub ahead of print. PMID: 33155906. 28. Lengyel CG, Habeeb B, Khan SZ, El Bairi K, Altuna SC, Hussain S, Mazher SA, Trapani D & Petrillo A. Role of Her_2 in Gastrointestinal Tumours beyond Gastric Cancer: A Tool for Precision Medicine. *Gastrointestinal Disorders*. 2021; 3(1):1_22. <https://doi.org/10.3390/gidisord3010001> 29. Trapani, D., Giugliano, F., El Bairi, K., Uliano, J., Belli, C., & Curigliano, G. (2021). Caveats, Nuances and Benefits of the Clinical Use of granulocyte Colony_Stimulating Factors in Cancer Patients with Coronavirus Disease 2019. *Cancer Cells and Therapy*, 1(1), 1_7. Retrieved from <https://www.medcliph.com/index.php/cct/article/view/530>. El Bairi K, Trapani D, Petrillo A, Le Page C, Zbakh H, Daniele B, Belbaraka R, Curigliano G, Afqir S. Repurposing anticancer drugs for the management of COVID_19. *Eur J Cancer*. 2020 Dec;141:40_61. doi: 10.1016/j.ejca.2020.09.014. Epub 2020 Sep 22. PMID: 33125946; PMCID: PMC7508523. 31. Petrillo A, Salati M, Trapani D, Ghidini M. Circulating Tumor DNA as a Biomarker for Outcomes Prediction in Colorectal Cancer Patients. *Curr Drug Targets*. 2020 Nov 3. doi: 10.2174/1389450121999201103194248. Epub ahead of print. PMID: 33155906. 32. Lemine Sow M, El Yacoubi H, Moukafih B, Balde S, Akimana G, Najem S, El Khoyaali S, Abahssain H, Chaibi A, Zeb Khan S, Trapani D, Benzekri A, Ghaoui M, Gamra L, Mestari A, Kettani F, Rahali Y, Mrabti H, Elghissassi I, Errihani H. Frequency and types of EGFR mutations in Moroccan patients with non_small cell lung cancer. *Tumori*. 2020 Oct 20:300891620964571. doi: 10.1177/0300891620964571. Epub ahead of print. PMID: 33079008. 33. Ottaviano M, Curvietto M, Rescigno P, Tortora M, Palmieri G, Giannarelli D, Aietta M, Assalone P, Attademo L, Avallone A, Bloise F, Bosso D, Borzillo V, Buono G, Calderoni G, Caputo F, Carteni G, Cavallero D, Cavo A, Ciardiello F, Conca R, Contedua V, De Falco S, De Felice M, De Laurentiis M, De Placido P, De Placido S, De Santo I, De Stefano A, Della Corte CM, Di Franco R, Di Lauro V, Fabbrocini A, Federico P, Festino L, Giordano P, Giuliano M, Gridelli C, Grimaldi AM, Lia M, Marretta AL, Massa V, Mennitto A, Merler S, Merz V, Messina C, Messina M, Milano M, Minisini AM, Montesarchio V, Morabito A, Morgillo F, Mucci B, Nappi L, Napolitano F, Paciolla I, Pagliuca M, Palmieri G, Parola S, Pepe S, Petrillo A, Piantadosi F, Piccin L, Picozzi F, Pietroluongo E, Pignata S, Prati V, Riccio V, Rosanova M, Rossi A, Russo A, Salati M, Santabarbara G, Sbrana A, Simeone E, Silvestri A, Spada M, Tarantino P, Taveggia P, Tomei F, Vincenzo T, Trapani D, Trojanello C, Vanella V, Vari S, Ventriglia J, Vitale MG, Vitiello F, Vivaldi C, von Arx C, Zacchi F, Zampiva I, Zivi A, Daniele B, Ascierto PA; SCITO (Società Campana di ImmunoTerapia Oncologica). Impact of COVID_19 outbreak on cancer immunotherapy in Italy: a survey of young oncologists. *J Immunother Cancer*. 2020 Oct;8(2):e001154. doi: 10.1136/jitc_2020_001154. PMID: 33060148; PMCID: PMC7565202. 34. Canfell K, Kim JJ, Brisson M, Keane A, Simms KT, Caruana M, Burger EA, Martin D, Nguyen DTN, Bénard É, Sy S, Regan C, Drolet M, Gingras G, Laprise JF, Torode J, Smith MA, Fidarova E, Trapani D, Bray F, Ilbawi A, Broutet N, Hutubessy R. Mortality Impact of Achieving WHO Cervical Cancer Elimination Targets: A Comparative Modelling Analysis in 78 Low_Income and Lower_Middle_Income Countries. *Lancet*. 2020 Feb 22;395(10224):591_603. doi: 10.1016/S0140_6736(20)30157_35. Trapani D, Zagami P, Nicolò E, Pravettoni G, Curigliano G. Management of Cardiac Toxicity Induced by Chemotherapy. *J Clin Med*. 2020 Sep 7;9(9):E2885. doi: 10.3390/jcm9092885. PMID: 32906611. 36. Corti C, Crimini E, Criscitiello C, Trapani D, Curigliano G. Adjuvant treatment of early male breast cancer. *Curr Opin Oncol*. 2020 Aug 26. doi: 10.1097/CCO.0000000000000678. Epub ahead of print. PMID: 32852309. 37. Trapani D, Curigliano G. How to treat lobular cancer in the adjuvant setting? *Curr Opin Oncol*. 2020 Aug 19. doi: 10.1097/CCO.0000000000000674. Epub ahead of print. PMID: 32826487. 38. Curigliano G, Banerjee S, Cervantes A, Garassino MC, Garrido P, Girard N, Haanen J, Jordan K, Lordick F, Machiels JP, Michielin O, Peters S, Tabernero J, Douillard JY, Pentheroudakis G; Panel members. Managing cancer patients during the COVID_19 pandemic: an ESMO multidisciplinary expert consensus. *Ann Oncol*. 2020 Oct;31(10):1320_1335. doi: 10.1016/j.annonc.2020.07.010. Epub 2020 Jul 31. PMID: 32745693 (panel member) 39. Trapani D, Curigliano G, Alexandru E, Sternberg CN. The global landscape of drug development for kidney cancer. *Cancer Treat Rev*. 2020

Sep;89:102061. doi: 10.1016/j.ctrv.2020.102061. Epub 2020 Jun 23. PMID: 32738737. 40. Duso BA, Trapani D, Marra A, D'Amico P, Guerini Rocco E, Fusco N, Mazzarella L, Criscitiello C, Esposito A, Curigliano G. Pharmacological management of male breast cancer. *Expert Opin Pharmacother*. 2020 Aug;21(12):1493-1504. doi: 10.1080/14656566.2020.1763305. Epub 2020 Jun 4. PMID: 32496137. 41. de Azambuja E*, Trapani D*, Loibl S, Delaloge S, Senkus E, Criscitiello C, Poortman P, Gnant M, Di Cosimo S, Cortes J, Cardoso F, Paluch-Shimon S, Curigliano G. ESMO Management and treatment adapted recommendations in the COVID_19 era: Breast Cancer. *ESMO Open*. 2020 May;5(Suppl 3):e000793. doi: 10.1136/esmoopen.2020.000793. PMID: 32439716; PMCID: PMC7295852. *co_first 42. Trapani D, Marra A, Curigliano G. The experience on coronavirus disease 2019 and cancer from an oncology hub institution in Milan, Lombardy Region. *Eur J Cancer*. 2020 Jun;132:199-206. doi: 10.1016/j.ejca.2020.04.017. Epub 2020 Apr 29. PMID: 32380430; PMCID: PMC7188643. 43. Pietrantonio F, Loupakis F, Randon G, Raimondi A, Salati M, Trapani D, Pagani F, Depetris I, Maddalena G, Morano F, Corallo S, Prisciandaro M, Corti F, Guarini V, Bocconi A, Marra A, Belli C, Spallanzani A, Fassin M, Lonardi S, Curigliano G, Fucà G, Di Bartolomeo M, de Braud F. Efficacy and Safety of Immune Checkpoint Inhibitors in Patients with Microsatellite Instability_High End_Stage Cancers and Poor Performance Status Related to High Disease Burden. *Oncologist*. 2020 May 5;25(9):803-9. doi: 10.1634/theoncologist.2020.0014. Epub ahead of print. PMID: 32369650; PMCID: PMC7485362. 44. Tarantino P, Hamilton E, Tolane SM, Cortes J, Morganti S, Ferraro E, Marra A, Viale G, Trapani D, Cardoso F, Penault-Llorca F, Viale G, André F, Curigliano G. HER2_Low Breast Cancer: Pathological and Clinical Landscape. *J Clin Oncol*. 2020 Jun 10;38(17):1951-1962. doi: 10.1200/JCO.19.02488. Epub 2020 Apr 24. PMID: 32330069. 45. El Bairi K, Jabi R, Trapani D, Boutallaka H, Ouled Amar Bencheikh B, Bouziane M, Amrani M, Afqir S, Maleb A. Can the microbiota predict response to systemic cancer therapy, surgical outcomes, and survival? The answer is in the gut. *Expert Rev Clin Pharmacol*. 2020 Apr;13(4):403-421. doi: 10.1080/17512433.2020.1758063. Epub 2020 May 24. PMID: 32308061. 46. Tarantino P, Trapani D, Curigliano G. Conducting phase 1 cancer clinical trials during the severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)-related disease pandemic. *Eur J Cancer*. 2020 Jun;132:8-10. doi: 10.1016/j.ejca.2020.03.023. Epub 2020 Apr 6. PMID: 32305011; PMCID: PMC7136890. 47. Mazzarella L, Morganti S, Marra A, Trapani D, Tini G, Pellicci P, Curigliano G. Master protocols in immuno-oncology: do novel drugs deserve novel designs? *J Immunother Cancer*. 2020 Mar;8(1):e000475. doi: 10.1136/jitc.2019.000475. PMID: 32238471; PMCID: PMC7174064. 48. Passaro A, Mackenzie G, Lambertini M, Morgan G, Zimmermann S, Garrido P, Curigliano G, Trapani D. European Society for Medical Oncology (ESMO) 2018 Congress Twitter Analysis: From Ethics to Results Through the Understanding of Communication and Interaction Flows. *ESMO Open*. 2020 Feb;5(1):e000598. doi: 10.1136/esmoopen.2019.000598. 49. Trapani D, Curigliano G. How can biosimilars change the trajectory of breast cancer therapy? (Editorial) *Expert Rev Anticancer Ther*. 2020 May;20(5):325-328. doi: 10.1080/14737140.2020.1757438. Epub 2020 Apr 28. PMID: 32298188. 50. Curigliano G, Bagnardi V, Ghioni M, Louahed J, Richard V, Lehmann FF, Marra A, Trapani D, Criscitiello C, Viale G. Expression of tumor-associated antigens in breast cancer subtypes. *Breast* 2019 51. Trapani D, Curigliano G, Eniu A. Breast Cancer: Reimbursement Policies and Adoption of New Therapeutic Agents by National Health Systems. *Breast Care (Basel)*. 2019 Dec;14(6):373-381. doi: 10.1159/000502637. Epub 2019 Sep 24. PMID: 31933583; PMCID: PMC6940432. 52. Lengyel CG, Altuna SC, Habeeb BS, Trapani D, Khan SZ. The Potential of PI3K/AKT/mTOR Signaling as a Druggable Target for Endometrial and Ovarian Carcinomas. *Curr Drug Targets* 2019 53. Ferraro E, Trapani D, Marrucci E, Curigliano G. Evaluating triptorelin as a treatment option for breast cancer. *Expert Opin Pharmacother* 2019 54. Romero Y*, Trapani D*, Johnson S, Tittenbrun Z, Given L, Hohman K, Stevens L, Torode JS, Boniol M, Ilbawi AM. National cancer control plans: a global analysis. *Lancet Oncol*. 2018. 55. Mazzarella, Duso BA, Trapani D, Belli C, D'Amico P, Ferraro E, Viale G, Curigliano G. The evolving landscape of 'next-generation' immune checkpoint inhibitors: A review. *Eur J Cancer*. 2019 56. Eniu A, Cherny NI, Bertram M, Thongprasert S, Douillard JY, Bricalli G, Vyas M, Trapani D. Cancer medicines in Asia and Asia-Pacific: What is available and is it effective enough? *ESMO Open* 2019 57. Trapani D, Rajasekar AKA, Mathew A. More options for adjuvant treatment of HER2-positive breast cancer: How to choose wisely? *Int J Cancer*. 2019 58. Willenbacher E, Khan SZ, Mujica SCA, Trapani D, Hussain S, Wolf D, Willenbacher W, Spizzo G, Seeber A. Curcumin: New Insights into an Ancient Ingredient against Cancer. *Int J Mol Sci*. 2019 59. Morganti S, Tarantino P, Ferraro E, D'Amico P, Viale G, Trapani D, Duso BA, Curigliano G. Complexity of genome sequencing and reporting: Next generation sequencing (NGS) technologies and implementation of precision medicine in real life. *Crit Rev Oncol Hematol*. 2019 60. Belli C, Zuin M, Mazzarella C, Trapani D, D'Amico P, Guerini Rocco E, Achutti Duso B, Curigliano G. Liver toxicity in the era of immune checkpoint inhibitors: a practical approach. *Critical Reviews in Oncology Hematology*, 2018. 61. Duso BA, Trapani D, Viale G, Criscitiello C, D'Amico P, Belli C, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Clinical efficacy of ribociclib as a first-line therapy for HR-positive, advanced breast cancer. *Expert Opin Pharmacother*. 2018. 62. Belli C, Trapani D, Viale G, D'Amico P, Duso BA, Della Vigna P, Orsi F, Curigliano G. Targeting the microenvironment in solid tumors. *Cancer Treat Rev*. 2018. 63. Giulia Viale, Dario Trapani, and Giuseppe Curigliano, "Mismatch Repair Deficiency as a Predictive Biomarker for Immunotherapy Efficacy," *BioMed Research International*, vol. 2017, Article ID 4719194, 7 pages, 2017. 64. Trapani D, Criscitiello C, Esposito A, Mazzarella L, Locatelli M, Minchella I, Curigliano G. Entinostat for the treatment of breast cancer. *Expert Opin Investig Drugs*. 2017. 65. Esposito A, Criscitiello C, Trapani D, Curigliano G. The Emerging Role of "Liquid Biopsies," Circulating Tumor Cells, and Circulating Cell-Free Tumor DNA in Lung Cancer Diagnosis and Identification of Resistance Mutations. *Curr Oncol Rep*. 2017 Jan;19(1):1. 66. Migali C, Milano M, Trapani D, Criscitiello C, Esposito A, Locatelli M, Minchella I, Curigliano G. Strategies to modulate the immune system in breast cancer: checkpoint inhibitors and beyond. *Therapeutic advances in medical oncology*, July 2015. 67. Trapani D, Curigliano G. Genomic analysis of circulating tumor DNA to predict endocrine resistance and clonal evolution in patients with prostate cancer: Clinical perspectives and research opportunities. *Transl Cancer Res* 2016;5(Suppl 4):S800-S802. 68. Criscitiello C, Esposito A, Trapani D, Curigliano G. Prognostic and predictive value of tumor infiltrating lymphocytes in early breast cancer. *Cancer Treat Rev*. 2016 Oct 6;50:205-207. 69. Trapani D, Conforti F, De Pas M. EGFR inhibition in a pretreated sacral chordoma: a role for erlotinib? Case report and a brief review of literature. *Tras med* 2015. 70. Trapani D, Bonzi M. Antibiotic treatment strategies for community-acquired pneumonia in adults. The cutting edge: research update. *Internal and Emergency Medicine* (October 2015), 10(7): 861- 863.

Projects

TECHNICAL WORKING GROUPS • ESMO Leaders Generation Program (LGP 2019 class) • ESMO Faculty – Breast Cancer (2020_2021) • ESMO Media & Press committee – committee member (2019_2021) • ESMO Public Policy committee (2021) • ESMO Magnitude of Clinical Benefit Working Group (2020_2021) • ESMO Precision Medicine Working Group for treatment individualization (de-escalation) of antineoplastic therapies (2021) • WHO Cancer Essential Medicines (EML) Working Group (2020_2021) • WHO SAGE for essential diagnostic in vitro (EDL) (2021_) • WHO Global Breast Cancer Initiative Working Group (2021_) • ONCOLLEGE Global Oncology Project – Secretary (2019_) • DECIDE health decision hub (WHO_hosted, Bill & Melinda Gates Foundation) – member • ESMO Annual Congress (Paris) 2021, Scientific Committee – Public Policy • ESMO framework for the determination of the Lines of Therapies (LoT) (2021_2022) • Tenwek Mission Hospital, Kenya: expert member of the Tumor Board _ breast cancer (2019_)

Memberships

MEMBERSHIP OF SOCIETIES Italian Oncology Association (AIOM) European Society of Medical Oncology (ESMO) ESO (European School of Oncology) American Society of Clinical Oncology (ASCO)

Other Relevant Information

JOURNAL CURRENT EDITOR □ Journal of Cancer Policy – member of the Editorial Board □ ESMO Perspectives (magazine) – member of the Editorial Board □ Columnist for ESMO Perspectives (Sustainability of Cancer Care)